Anti-Coagulation Factor XI Antibodies
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 6 of these applications claim priority to application 62/349,888, filed Jun 14, 2016. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 12,275,800 | Anti-Coagulation Factor XI Antibodies In force · Medium confidence | Merck Sharp & Dohme LLC | In force | Medium confidence | ||
| US 11,661,460 | Anti-Coagulation Factor XI Antibodies In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | ||
| US 10,676,536 | Anti-Coagulation Factor XI Antibodies In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | ||
| US 11,512,142 | Anti-Coagulation Factor XI Antibodies In force · Medium confidence | Merck Sharp & Dohme LLC | In force | Medium confidence | ||
| US 11,479,615 | Anti-Coagulation Factor XI Antibodies In force · Medium confidence | Merck Sharp & Dohme LLC | In force | Medium confidence | ||
| US 11,485,794 | Anti-Coagulation Factor XI Antibodies In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence |
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.